Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Abstract Text:

O E Young,L Renshaw,E J Macaskill,S White,D Faratian,J St J Thomas,J M Dixon,

Fulvestrant (Faslodextrade mark) is a pure anti-oestrogen that reduces markers of hormone sensitivity and proliferation in postmenopausal women with oestrogen-receptor (ER)-positive breast cancer. This randomised trial compared the effects on the tumours of a single dose of 750mg fulvestrant to those of daily tamoxifen (20mg) taken 14-16 days prior to surgery in 60 premenopausal women with ER-positive primary breast cancer. There were statistically significant falls in the expression of ER and Ki67 levels compared to the baseline with both drugs. Both drugs caused a decrease in PgR expression from baseline but this was only statistically significant with fulvestrant. No statistically significant differences were seen between the two treatment groups. Fulvestrant caused an increase in circulating levels of oestradiol, irrespective of the stage of the menstrual cycle at which patients commenced treatment. No major changes were seen in LH, FSH and progesterone levels with either drug. The most common adverse events with fulvestrant were headaches, hot flushes, nausea and disturbance of menses. Contrary to previous studies with fulvestrant 250mg, these findings suggest that at a dose of 750mg fulvestrant is effective at reducing the effects of oestrogen on ER-positive breast cancer in premenopausal women.

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Publishing Authors By Initials

OE Young,L Renshaw,EJ Macaskill,S White,D Faratian,JS Thomas,JM Dixon,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of cancer (Oxford, England : 1990

VOLUME: 44

Page Numbers: 391-9

Journal Abbreviation: Eur. J. Cancer

ISSN: 0959-8049

DAY: 20

MONTH: 12

YEAR: 2007

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9005373

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.

AFFILIATION: Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer Related Publications

• A population-based needs assessment for mental health services.
• Adherence rates with infliximab therapy in Crohn's disease.
• Aromatase inhibitors--gene discovery.
• Cloning and characterization of a cDNA encoding walleye (Sander vitreum) beta-2 microglobulin.
• Delayed increase of tyrosine hydroxylase expression in rat nigrostriatal system after traumatic brain injury.
• Depressive symptoms, cardiovascular risk, and diabetes self-care strategies in African American women with type 2 diabetes.
• Embolic protection of saphenous vein graft percutaneous interventions.
• Gender associations with chronic methylphenidate treatment and behavioral performance following experimental traumatic brain injury.
• Heats of formation and singlet-triplet separations of hydroxymethylene and 1-hydroxyethylidene.
• Immunopathogenicity and oncogenicity of murine leukemia viruses. II. Infection of mice and rats with Scripps leukemia virus.
• Impact of patients' socioeconomic status on the distance travelled for hospital admission in the English National Health Service.
• Influence of salinity and fish species on PAH uptake from dispersed crude oil.
• Interactions of bacterial effector proteins with host proteins.
• Interactive effects of metals in mixtures on bioaccumulation in the amphipod Hyalella azteca.
• Molecular epidemiology of African swine fever virus studied by analysis of four variable genome regions.
• Predicting the energy of the water exchange reaction and free energy of solvation for the uranyl ion in aqueous solution.
• Ps14 factors influencing the timing of the exit procedure for obstructing fetal neck masses.
• Radiographic texture analysis of densitometer-generated calcaneus images differentiates postmenopausal women with and without fractures.
• Reliability of spot test kits for detecting lead in household dust.
• Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury.
• Site-isolated base- and acid-mediated Michael-initiated cyclization cascades.
• Special issue: membranes.
• Stimulatory and inhibitory effects of genistein on human uterine leiomyoma cell proliferation are influenced by the concentration.
• The cup is both half empty and half full.
• The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster.
• The participation of the Na+-Ca2+ exchanger in primary cardiac myofibroblast migration, contraction, and proliferation.
• The pds2 mutation is a lesion in the Arabidopsis homogentisate solanesyltransferase gene involved in plastoquinone biosynthesis.
• The phosphatase laforin crosses evolutionary boundaries and links carbohydrate metabolism to neuronal disease.
• The structure of acetyldihydrolipoic acid.
• Who should lead?